Abstract

Editorial: Biomarkers of Alzheimer's Disease: The Present and the Future.

Highlights

  • Alzheimer disease (AD) is a neurodegenerative disorder characterized by significant cognitive deficits, behavioral changes, sleep disorders, and loss of functional autonomy

  • AD represents the major cause of dementia and has become a major public health issue

  • New revised AD diagnostic criteria include alteration of cerebrospinal fluid (CSF) biomarkers: a decrease in concentrations of amyloid peptides (Aβ42) and an increase in tau and phosphorylated-tau (p-tau) protein concentration. This recognition of CSF biological biomarkers for diagnosis of AD is a major step toward the “molecular” diagnosis and follow-up of the disease

Read more

Summary

INTRODUCTION

Alzheimer disease (AD) is a neurodegenerative disorder characterized by significant cognitive deficits, behavioral changes, sleep disorders, and loss of functional autonomy. In the last two chapters, which focus on CSF and blood biomarkers, the different articles by Steen Jensen, Paquet, Lopez-Font, Zhao, Herbert, Inekci, Delaby, Fiandaca, and Baird propose new biomarkers such as plasma proteins of amyloid pathology, miRNA, cytokines, kinases, axonal proteins, lipids, and fragments of already known markers These articles give valuable insight into the novel approaches which could result in the identification of biomarkers useful in the field of diagnosis or therapeutic trials. CSF biomarkers are increasingly implemented in clinical routine to sustain the diagnosis of dementias knowing that there is a strong need for accurate, sensitive, and reliable biomarkers for AD This will help early diagnosis, targeted therapeutics, prognosis, and follow-up of patients. We are pleased that the current research topic gives a comprehensive state of the art of the use of the biomarkers, and projects good faith into the implementation of well-validated novel biomarkers for dementia in the future

Chapter 1: State of the Art of CSF Amyloid Peptides and Tau Proteins Analysis
Chapter 3: Novel CSF Biomarkers of Dementias
Blood-Based Proteomic Biomarkers of Alzheimer’s Disease Pathology

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.